Johnson & Johnson (JNJ) Holdings Boosted by Boston Advisors LLC

Boston Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 32.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,364 shares of the company’s stock after purchasing an additional 22,318 shares during the quarter. Boston Advisors LLC’s holdings in Johnson & Johnson were worth $12,765,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Landmark Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the last quarter. Premier Asset Management LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares during the last quarter. Lbmc Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after purchasing an additional 14 shares during the last quarter. Halbert Hargrove Russell LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after purchasing an additional 15 shares during the last quarter. Finally, Lenox Wealth Management Inc. increased its holdings in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 67.24% of the company’s stock.

How to Become a New Pot Stock Millionaire

JNJ has been the subject of several recent research reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a report on Thursday, January 11th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday, February 26th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 target price for the company in a research note on Wednesday, March 28th. Finally, TheStreet cut Johnson & Johnson from an “a” rating to a “c+” rating in a research note on Monday, March 26th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $144.03.

In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.22% of the company’s stock.

JNJ opened at $130.62 on Monday. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32. The firm has a market cap of $349,930.91, a PE ratio of 17.89, a PEG ratio of 2.07 and a beta of 0.74. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. During the same period last year, the business posted $1.58 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. equities research analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/16/johnson-johnson-jnj-holdings-boosted-by-boston-advisors-llc.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply